Background
==========

Down syndrome (DS) is the most frequent genomic aneuploidy with an incidence of approximately 1 in 700 live-newborn \[[@B1]\] resulting from the presence of an extra copy of human chromosome 21 (HSA21). DS is characterized by a complex phenotype with features that are not fully penetrant. The most frequent manifestations, which are virtually always present, include mental retardation, morphological abnormalities of the head and limbs, short stature, hypotonia and hyperlaxity of ligaments. Other features occur with less frequency such as organ malformations, particularly of the heart (50% of DS newborns), several types of gastrointestinal tract obstructions or dysfunctions (4-5% of DS newborns), increased risk of leukaemia (20 × higher compared to the normal population), and early occurrence of an Alzheimer-like neuropathology \[[@B2],[@B3]\]. DS has been investigated with multiple functional genomics studies aiming to understand the molecular basis underlying the various aspects of the disease \[[@B4]-[@B7]\].

The most commonly accepted pathogenetic hypothesis is that the dosage imbalance of genes on HSA21 is responsible for the molecular dysfunctions in DS, meaning that genes on the triplicated chromosome are overexpressed due to an extra chromosome 21, as demonstrated for selected genes like *SOD1*and *DYRK1A*\[[@B8]\]. Recent global transcriptome studies with microarrays, however, have generated a more complex picture in the sense that not all HSA21 genes have an elevated expression level as expected \[[@B9],[@B10]\]. An alternative hypothesis is that the phenotype is due to an unstable environment resulting from the dosage imbalance of the hundreds of genes on HSA21 which determines a non-specific disturbance of genomic regulation and expression. The significantly higher inter-individual variability in DS, as compared to euploid, individuals supports this hypothesis \[[@B11]\]. Moreover, the two hypotheses could be coexistent \[[@B3]\]. In both hypotheses it is understood that besides alterations of gene expression of HSA21 genes there are numerous genome-wide effects that lead to the dysregulation of many non-HSA21 genes through molecular pathways and interactions.

Many studies on the transcriptome and proteome levels have been conducted to understand the causal relationship between genes at dosage imbalance and DS phenotypes \[[@B12]\]. Gene expression profiles have been analysed from DS fetal \[[@B13]\] and adult human tissues \[[@B6]\]. Additionally, two classes of mouse models \[[@B14]\] have been developed for investigating the molecular genetics of DS, either mouse models with partial trisomies of the syntenic regions of HSA21 in mouse chromosomes 10, 16 or 17, such as Ts16 \[[@B15]\], Ts65Dn \[[@B16]\] and Ts1Cje mice \[[@B17]\], or transgenic mice for specific genes such as *SOD1*\[[@B18]\]. Studies of gene expression profiles in human DS samples and mouse models have shown high genome-wide variability \[[@B11],[@B19]-[@B22]\]. Furthermore, differences due to the applied experimental platforms, specific tissues, developmental stages or the triplicated segments under study introduce a high variation to the assessment of genome-wide effects of DS. Here, integrative and comparative studies are pivotal for the analysis of the complex nature of gene expression and regulation in DS at a more general level \[[@B2],[@B23]\].

Meta-analysis was proven to be a valid strategy to extract consistent information from heterogeneous data, in particular with respect to complex phenotypes for example cancer \[[@B24]\], Alzheimer \[[@B25]\] and type-2 diabetes mellitus \[[@B26]\]. The purpose of meta-analysis is to compensate experiment-specific variations and to reveal consistent information across a wide range of experiments. To date, such a meta-analysis of DS data is missing.

In this paper we describe a comprehensive meta-analysis from 45 different DS studies on human and mouse on the transcriptome and proteome level including quantitative data such as Affymetrix microarrays, RT-PCR and MALDI studies as well as qualitative data such as SAGE and Western blot analyses. We applied an established computational framework \[[@B26]\] and identified 324 genes with consistent dosage effects in many of these studies. As expected, we observed a high fraction of HSA21 genes (N = 77) but also a large amount of non-HSA21 genes (N = 247). Besides well investigated genes in the context of DS we detected a significant proportion of novel ones (N = 62). The 324 genes were further investigated using functional information, molecular interactions and promoter analysis revealing over-represented motifs of four transcription factors: *RUNX1*, *E2F1*, *STAF/PAX2*and *STAT3*. In order to test the relevance of the 324 genes for more general brain phenotypes we used independent publicly available data on cerebral pathologies not related to DS and identified a subset of 79 DS genes that were differentially expressed in these studies. The detected dosage effects can be used as a resource for further studies of DS pathology, functional experiments and the development of therapies. All data have been agglomerated and made available through a web server that tracks results of the meta-analysis <http://ds-geneminer.molgen.mpg.de/> and that enables the community to validate any gene of interest in the light of the experimental data.

Results
=======

Genome-Wide Dosage Effects
--------------------------

Genome-wide dosage effects were computed with the numerical scoring method described in Material and Methods. In total, 45 case-control experiments were interrogated (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1), the alteration for each gene between the trisomic and normal states was scored in each experiment, gene scores were summarised across all experiments and the significance of the summarised scores was judged with a Bootstrap approach. This procedure resulted in a cut-off score value of 3.67 and identified 324 genes as being predominantly affected by DS. The thirty genes with the highest dosage effects, either on HSA21 or on other chromosomes, are listed in Table [1](#T1){ref-type="table"}. The entire gene list is given in Additional file [1](#S1){ref-type="supplementary-material"}, Table S2.

###### 

Top thirty DS dosage effects on A) HSA21 and B) other chromosomes

  --------------------------------------------------------------------------------------------------------------------------------------
  A\) Direct effects                                                                                                           
  ------------------------- ------------- ----------- ------------- ----------------- -------------- -------------- ---------- ---------
  **Ensembl**               **HUGO**      **Score**   **Entropy**   **Chromo-some**   **Start**\     **End**\       **Band**   **CNV**
                                                                                      **position**   **position**              

                                                                                                                               

  ENSG00000154734           ADAMTS1       18.487      4.083         chr21             28208606       28217728       q21.3      

  ENSG00000159228           CBR1          17.518      4.509         chr21             37442239       37445464       q22.12     

  ENSG00000159140           SON           15.920      4.712         chr21             34914924       34949812       q22.11     

  ENSG00000142168           SOD1          15.817      4.372         chr21             33031935       33041244       q22.11     

  ENSG00000182670           TTC3L, TTC3   15.637      4.542         chr21             38445526       38575413       q22.13     

  ENSG00000142192           APP           15.489      4.412         chr21             27252861       27543446       q21.3      

  ENSG00000159128           IFNGR2        15.006      4.640         chr21             34757299       34851655       q22.11     

  ENSG00000182240           BACE2         14.156      4.140         chr21             42539728       42648524       q22.2      

  ENSG00000156256           USP16         13.713      4.378         chr21             30396950       30426809       q21.3      

  ENSG00000159131           GART          13.570      4.564         chr21             34870940       34915797       q22.11     

  ENSG00000157540           DYRK1A        13.163      4.405         chr21             38739236       38887680       q22.13     

  ENSG00000157557           ETS2          13.088      4.440         chr21             40177231       40196879       q22.2      

  ENSG00000159231           CBR3          12.185      3.954         chr21             37507210       37518864       q22.12     YES

  ENSG00000159082           SYNJ1         11.880      4.284         chr21             33997269       34100359       q22.11     

  ENSG00000142188           TMEM50B       11.516      3.803         chr21             34804792       34853499       q22.11     YES

  ENSG00000159110           IFNAR2        11.280      4.360         chr21             34602206       34656082       q22.11     

  ENSG00000157538           DSCR3         11.254      4.316         chr21             38591910       38640262       q22.13     

  ENSG00000157601           MX1           10.976      3.545         chr21             42792231       42831141       q22.3      

  ENSG00000159267           HLCS          10.764      4.183         chr21             38123493       38362536       q22.13     YES

  ENSG00000159200           RCAN1         10.719      3.356         chr21             35885440       35987441       q22.12     

  ENSG00000159147           DONSON        10.435      4.295         chr21             34947783       34961014       q22.11     

  ENSG00000156261           CCT8          10.361      4.560         chr21             30428126       30446118       q21.3      

  ENSG00000183486           MX2           10.179      3.598         chr21             42733870       42781317       q22.3      

  ENSG00000154727           GABPA         9.936       4.032         chr21             27106881       27144771       q21.3      

  ENSG00000160200           CBS           9.284       3.907         chr21             44473301       44497053       q22.3      

  ENSG00000159216           RUNX1         9.129       3.783         chr21             36160098       37357047       q22.12     

  ENSG00000183527           PSMG1         8.903       3.733         chr21             40546695       40555777       q22.2      

  ENSG00000182093           WRB           8.837       4.149         chr21             40752170       40800454       q22.2      

  ENSG00000154736           ADAMTS5       8.746       4.221         chr21             28290231       28338832       q21.3      

  ENSG00000159197           KCNE2         8.654       3.660         chr21             35736323       35743440       q22.11     YES

                                                                                                                               

  **B) Indirect effects**                                                                                                      

                                                                                                                               

  **Ensembl**               **HUGO**      **Score**   **Entropy**   **Chromo-some**   **Start**\     **End**\       **Band**   **CNV**
                                                                                      **position**   **position**              

                                                                                                                               

  ENSG00000117289           TXNIP         8.790       3.281         chr1              145438469      145442635      q21.1      YES

  ENSG00000133110           POSTN         8.301       2.437         chr13             38136722       38172981       q13.3      YES

  ENSG00000118785           SPP1          7.232       3.159         chr4              88896802       88904563       q22.1      

  ENSG00000113140           SPARC         7.035       3.338         chr5              151040657      151066726      q33.1      

  ENSG00000125968           ID1           6.987       3.164         chr20             30193086       30194318       q11.21     

  ENSG00000136235           GPNMB         6.943       2.047         chr7              23275586       23314727       p15.3      

  ENSG00000171951           SCG2          6.747       2.950         chr2              224461658      224467221      q36.1      

  ENSG00000135821           GLUL          6.604       3.702         chr1              182350839      182361341      q25.3      

  ENSG00000123610           TNFAIP6       6.575       2.377         chr2              152214106      152236560      q23.3      

  ENSG00000118523           CTGF          6.567       2.996         chr6              132269316      132272513      q23.2      

  ENSG00000168209           DDIT4         6.477       3.318         chr10             74033678       74035794       q22.1      

  ENSG00000162407           PPAP2B        6.350       3.343         chr1              56960419       57110974       p32.2      

  ENSG00000038427           VCAN          6.240       2.958         chr5              82767284       82878122       q14.2      

  ENSG00000151491           EPS8          6.194       3.143         chr12             15773076       15942510       p12.3      

  ENSG00000189067           LITAF         6.185       3.255         chr16             11641582       11680806       p13.13     

  ENSG00000164692           COL1A2        6.148       2.852         chr7              94023873       94060544       q21.3      

  ENSG00000204388           HSPA1B        6.109       2.550         chr6              31795688       31798031       p21.33     

  ENSG00000162692           VCAM1         6.012       2.533         chr1              101185305      101204601      p21.2      

  ENSG00000154096           THY1          5.974       3.244         chr11             119288888      119293854      q23.3      

  ENSG00000135919           SERPINE2      5.904       3.048         chr2              224839765      224904036      q36.1      

  ENSG00000172201           ID4           5.887       3.037         chr6              19837617       19840915       p22.3      

  ENSG00000114315           HES1          5.884       2.874         chr3              193853934      193856521      q29        

  ENSG00000172893           DHCR7         5.883       3.441         chr11             71145457       71159477       q13.4      

  ENSG00000204262           COL5A2        5.857       3.174         chr2              189896622      190044605      q32.2      

  ENSG00000149257           SERPINH1      5.846       3.146         chr11             75273170       75283844       q13.5      

  ENSG00000176697           BDNF          5.805       2.416         chr11             27676440       27743605       p14.1      

  ENSG00000182551           ADI1          5.782       3.081         chr2              3501693        3523507        p25.3      

  ENSG00000079739           PGM1          5.661       3.251         chr1              64058947       64125916       p31.3      

  ENSG00000108821           COL1A1        5.527       3.004         chr17             48260650       48278993       q21.33     

  ENSG00000187498           COL4A1        5.514       3.396         chr13             110801318      110959496      q34        
  --------------------------------------------------------------------------------------------------------------------------------------

The meta-analysis identified genes that showed consistent changes in many of the different experiments rather than genes that were affected by a single (or few) experiment(s) (Figure [1A](#F1){ref-type="fig"}). This is an important fact since, for example, different mouse models have different coverage of triplicated HSA21 genes, and, thus, might introduce model-specific bias \[[@B14]\]. The consistency of the dosage effect was measured for each gene with an entropy criterion (see Materials and Methods) and Figure [1A](#F1){ref-type="fig"} reveals a strong preference for the selection of high-entropy genes. Highest scores were assigned to HSA21 genes (Figure [1B](#F1){ref-type="fig"}) what indicates that the meta-analysis scores reflect the effect of an extra chromosome 21 on gene expression (Table [1](#T1){ref-type="table"}). While proportionally most dosage effects were identified for HSA21 genes (77 out of 324), the majority of genes (247 out of 324) was located on other chromosomes highlighting the genome-wide impact of DS (Figure [1C](#F1){ref-type="fig"}).

![**Characterization of dosage effects**. A) Entropy (Y-axis) vs. score of dosage effect (X-axis) for all genes, B) Histogram of scores for all 255 HSA21 genes accessible with the experiments under study, C) Distribution of genomic locations of the 324 candidate genes, D) Cytogenetic location of 77 HSA21 genes that show significant dosage effects for all experiments (blue line). Additionally, the same meta-analysis approach has been conducted with human (green line) and mouse (red line) data separately. The yellow line plots the relative number of HSA21 genes within each band (gene density). Y-axis shows percentage of significant genes with respect to all genes annotated for the chromosomal band.](1471-2164-12-229-1){#F1}

Genome-wide dosage effects underlined the severe phenotypic consequences of DS caused by genes with a major role in human development (Additional file [2](#S2){ref-type="supplementary-material"}, Figure S1). Of the 247 non-HSA21 genes, 72 were associated with development, in particular with respect to organ development (62 genes, GO:0048513), tissue development (34 genes GO:0009888) and cell development (30 genes, GO:0048468). Amongst these genes were known interactors of HSA21 genes, for example *REST*(RE1-silencing transcription factor). *REST*modulates expression of genes encoding fundamental neuronal functions including ion channels, synaptic proteins and neurotransmitter receptors and has been linked to an inherited form of mental retardation. Recently, Canzonetta et al. \[[@B5]\] demonstrated that the region capable of affecting *REST*levels, in both mouse and human cells, could be assigned to the *DYRK1A*locus on HSA21 which was found among the top-scoring HSA21 genes (Table [1](#T1){ref-type="table"}).

*TXNIP*(thioredoxin interacting protein) had the highest dosage effect (8.79) of all non-HSA21 genes. It has weak association with DS yet (through *S100B*\[[@B27]\]) but could play a major role for several DS phenotypes. It is a key signalling molecule involved in glucose homeostasis \[[@B28]\], cardiovascular homeostasis \[[@B29]\] and leukaemia \[[@B30]\].

Enrichment of genomic location with respect to the 324 genes was observed in regions of HSA21 and the respective syntenic regions on mouse chromosomes 16, 17 and 10 (Additional file [3](#S3){ref-type="supplementary-material"}, Figure S2). Moreover, in the human genome, additional enrichment on chr3q24 was computed containing the genes *GYG1*(glicogenin), *PLOD2*(involved in bone morphogenesis), *PLSCR4*and *CHST2*(involved in inflammatory response in vascular endothelial cells).

Dosage Effects on HSA21
-----------------------

Proportionally HSA21 contributed mostly to the detected dosage effects (Figure [1C](#F1){ref-type="fig"}). On the other hand, it is remarkable that only a third of all HSA21 genes (77 out of 255 studied here using the Ensembl genome annotation \[[@B31]\]) showed consistent effects across the different experiments (see also Discussion). While 57 genes had a positive score below the significance threshold of 3.67 indicating relevance with respect to specific experiments only, 121 genes had a score near zero indicating that dosage effects were either compensated or not detected with the selected experimental data (Figure [1B](#F1){ref-type="fig"}).

HSA21 dosage effects included, for example *APP*(beta-amyloid precursor protein) involved in senile plaque formation in DS and Alzheimer\'s disease \[[@B3]\], *SOD1*(superoxide dismutase 1), a key enzyme in the metabolism of oxygen-derived free radicals \[[@B3]\], *DYRK1A*(dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) involved in neuroblast proliferation, crucial for brain function, learning and memory \[[@B32]\], *RUNX1*(runt-related transcription factor 1) which plays a critical role in normal hematopoiesis \[[@B33]\], or *GABPA*(GA binding protein transcription factor, alpha subunit 60 kDa) encoding a DNA binding domain with a huge variety of targets including genes from different cell/tissue specificities and functions \[[@B34]\]. HSA21 genes were mostly up-regulated in gene expression studies (69 out of 77) with the exception of eight genes that were either variable or down-regulated (*SLC5A3*, *MRPS6*, *B3GALT6*, *CBS*, *KCNJ6*, *KCNJ15*, *CLDN14*, *COL18A1*). Possible explanations for this observation might be tissue-specificity of gene expression as in the case of *MRPS6*which was mostly up-regulated in brain samples and down-regulated in other tissues like heart or kidney, or differences in human and mouse gene expression as in the case of *CBS*which was up-regulated in human but down-regulated in mouse experiments what might be caused by differential tissue specificity of the orthologous mouse gene \[[@B35]\].

Three genomic regions on HSA21 were enriched with the significant genes using the MSigDB_c1 positional database: chr21q22, chr21q21 and chr21q11, located on the q-terminal arm (Figure [1D](#F1){ref-type="fig"}). This contradicts the hypothesis that a single region on HSA21 could be responsible for the molecular and phenotypic consequences of DS with only a few responsive genes \[[@B36],[@B37]\]. Rather our findings support studies that identified more than one HSA21 region causative for DS phenotypes so that the dosage effects were not uniformly distributed along the chromosome but rather enriched in certain regions on HSA21 similar to the results in \[[@B38],[@B39]\].

Functional Annotation Using Gene Enrichment Analysis
----------------------------------------------------

Functional annotation of biological pathways was retrieved from the ConsensusPathDB \[[@B40]\], a meta-database that summarizes the content of 22 human interaction databases. A total of 1,695 pre-defined pathways were screened with the 324 genes using gene set enrichment analysis \[[@B41]\]. A total of 277 pathways were found significantly enriched (family-wise error rate (FWER)\<0.01) of which several pathways were associated with neurological and neuropathological processes (Table [2](#T2){ref-type="table"}). These pathways referred mainly to *(i)*neurodegeneration (e.g. *Huntington\'s disease, Alzheimer\'s disease or Parkinson\'s disease*) and *(ii)*defects in synapsis (e.g. *Axon guidance*, *NGF signaling*). Furthermore, the results emphasized the role of tyrosine-kinase receptors in DS pathology (for example *P75(NTR)- mediating signalling or NGF signalling via TRKA*) which interact directly with *BDNF*(brain-derived neurotrophic factor). Moreover, our results showed gene dosage effects caused either directly by genes located on HSA21 (e.g. *SOD1*, *APP*, *DONSON*, *TIAM1*, *COL6A2*, *ITSN1*and *BACE2*) or indirectly by HSA21 interactors, highlighting the intrinsic complexity of the DS pathology. For example, *PIK3R1*de-regulation impacts on many of these pathways and is a direct interactor of *IFNAR1*, a significant DS gene. A similar effect can be observed for *TPJ1A*that has interactions with HSA21 genes *JAM2*and *CDLN8*both showing consistent dosage effects (cf. Figure [2A](#F2){ref-type="fig"}).

###### 

Enriched neuropathological pathways.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PATHWAY (Source Database)                                     Pathway\   P-value   FWER P-value   Genes on HSA21       HSA21 Interactors                      Others
                                                                size                                                                                            
  ------------------------------------------------------------- ---------- --------- -------------- -------------------- -------------------------------------- -------------------------------------------------------------
  HUNTINGTONS DISEASE (KEGG)                                    159        0         0              SOD1; DONSON         REST                                   BDNF; SOD2

  ALZHEIMERS DISEASE (KEGG)                                     147        0         0              APP; BACE2; DONSON   PPP3CA; GSK3B                          CAPN2

  SIGNALLING BY NGF (REACTOME)                                  209        0         0              ITSN1; TIAM1         PIK3R1; GSK3B                          RPS6KA2; RAP1A; KRAS

  AXON GUIDANCE (REACTOME)                                      256        0         0              COL6A2               GSK3B;COL1A1; COL1A2; COL4A1; COL4A2   COL5A2; DPYSL3; RPS6KA2; LAMB1; COL3A1; COL5A1; ALCAM; KRAS

  PARKINSONS DISEASE (KEGG)                                     105        0         0              DONSON                                                      UBE2G2

  P75(NTR)-MEDIATED SIGNALING (PID)                             68         0         0              APP                  PIK3R1                                 BDNF

  NOTCH (NETPATH)                                               61         0         0              APP                  PIK3R1; GSK3B                          

  NEUROTROPHIN SIGNALING PATHWAY (KEGG)                         121        0         0                                   PIK3R1; GSK3B                          BDNF; RPS6KA2; RAP1A; KRAS

  NGF SIGNALLING VIA TRKA FROM THE PLASMA MEMBRANE (REACTOME)   127        0         0                                   PIK3R1; GSK3B                          RPS6KA2; RAP1A; KRAS

  MEMBRANE TRAFFICKING (REACTOME)                               87         0         0                                   TJP1                                   GJA1; COPG

  NEUROTROPHIC FACTOR-MEDIATED TRK RECEPTOR SIGNALING (PID)     60         0         0              TIAM1                PIK3R1                                 BDNF; RAP1A; KRAS

  EPO SIGNALING (INOH)                                          180        0         0                                   PIK3R1; GSK3B                          

  CDC42 SIGNALING EVENTS (PID)                                  68         0         0              TIAM1                PIK3R1; GSK3B                          EPS8; YES1

  L1CAM INTERACTIONS (REACTOME)                                 93         0         0                                                                          LAMB1; ALCAM1; RPS6KA2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![**Molecular interactions of HSA21 genes**. A) Interactions of HSA21 genes (red) with non-HSA21 genes (other colours). Same colours of the gene nodes refer to the same chromosome. B) Example of consistent down-regulation of *DNAJB1*as a consequence of HSA21 imbalance visualized in the web browser.](1471-2164-12-229-2){#F2}

Dosage Effects on Transcriptional Regulation
--------------------------------------------

Dysregulation of transcriptional regulation is widely reported in DS \[[@B34]\]. Among the 324 significant genes were 13 transcription factors (TFs) (*PSIP1, RBPJ, TCF4, HES1, ETS2, BACH1, RUNX1, GABPA, SNAI2, REST, LITAF, EGR1, FOS*), 6 TFs (*PSIP1, HOXC8, DLX5, HIVEP3, ZNF187, ATF6*) had significant enrichment of their targets as retrieved by the TRANSFAC \[[@B42]\] database. Additionally, 57 TFs had significant enrichment of their interacting proteins when judged with physical interactions retrieved from the ConsensusPathDB \[[@B40]\]. In total, 70 different TFs were identified as being (directly or indirectly) affected by dosage imbalances. The list of TFs and their associated functional categories is given in Additional file [1](#S1){ref-type="supplementary-material"}, Table S3. GO categories indicate a broad impact of transcriptional regulation for neurological development, the central nervous system development (*RUNX1*and *TP53*), nervous system development (*DLX5, FOS, HES1, STAT3*and *EP300*), axonogenesis (*DLX5*, *NOTCH1*and *CREB1*), neuron differentiation (*HOXC8*, *NOTCH1*and *RUNX1*), negative regulation of neuron differentiation (*HES1*, *NOTCH1*and *REST*) and regulation of long-term neuronal synaptic plasticity and learning or memory (*EGR1*and *JUN*). Other prominent categories refer to organ development (*RBPJ, ETS2, GABPA*and *SNAI2*) and stress response (*ATF6*, *FOS*and *RELA*).

We further analyzed the promoter sequences of the 324 genes for enrichment of transcription factor binding sites using the AMADEUS software \[[@B43]\]. Significant enrichment was computed for 4 TF motifs, *E2F1, RUNX1, STAF/PAX2*and *STAT3*(Table [3](#T3){ref-type="table"}). Enrichment was evident for *RUNX1*, which is among the most studied genes implicated in DS. The implication of *E2F1*in DS was also previously reported \[[@B34]\] and could be responsible for impaired cell proliferation documented for hippocampus, cerebellum and astrocytes of DS mouse models.

###### 

Enriched TFBSs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TF       Description                                                                        Cromo-some   P-Value        Binding motif                                                    Strand
  -------- ---------------------------------------------------------------------------------- ------------ -------------- ---------------------------------------------------------------- --------
  E2F1     E2F transcription factor 1                                                         chr20        9.3\*10^-18^   \[C/t\]\[C/a\]\[G/c\]C\[c/a\]\[C/g\]\[G/c\]\[C/T\]\[G/c\]A       \-

  RUNX1    runt-related transcription factor 1                                                chr21        4.0\*10^-18^   \[C/a/t\]\[T/a/g\]\[G/C\]{A}\[G/c\]{A}T\[C/A\]\[G\]\[C/a/t/g\]   \+

  STAF/\   paired box 2                                                                       chr10        8.4\*10^-18^   \[A/g\]\[A/g\]A\[C/T/a\]\[T/g/a\]\[T/c\]\[C/t\]\[C/g\]\[C/a\]    \+
  PAX2                                                                                                                                                                                     

  STAT3    signal transducer and activator of transcription 3 (acute-phase response factor)   chr17        8.4\*10^-17^   GAA\[A/T\]\[C/T\]G\[C/T\]\[C/g/t\]\[A/T\]\[C/T/g\]               \+
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Binding motifs have been represented using the IUPAC nomenclature and incorporating lower case for low frequency bases.

Dosage Effects and Molecular Interactions
-----------------------------------------

Molecular interactions among the 324 significant genes on HSA21 and on other chromosomes exhibited a complex network supporting the important role of physical interactions as transmitter of dosage effects (Figure [2A](#F2){ref-type="fig"}). The consequences of HSA21 triplication on the interacting genes was fairly stable as Figure [2B](#F2){ref-type="fig"} demonstrates. For example, *DNAJB1*(DnaJ (Hsp40) homolog, subfamily B, member 1) and *PPP3CA*(protein phosphatase 3, catalytic subunit, alpha isozyme, data not shown), both interacting with *SOD1*, were consistently and significantly down-regulated in the human microarray experiments as the fold-changes and P-values indicate. Opposite trends were observed for *TJP1*and *RHOQ*.

Assessing General Relevance of DS Dosage Effects for Neurological Processes
---------------------------------------------------------------------------

We were further interested in identifying, among the 324 genes, those which were relevant for other brain disorders. To achieve this, we interrogated 19 independent data sets derived from publicly available microarray data (Additional file [1](#S1){ref-type="supplementary-material"}, Table S4). These studies followed heterogeneous research questions on different cerebral pathologies and identified a total of 623 differentially expressed genes. Gene set enrichment analyses \[[@B41]\] with the 324 genes and the corresponding lists of differentially expressed genes were significant for 10 of these 19 studies with 79 overlapping genes (Figure [3A](#F3){ref-type="fig"}). Furthermore, we used the HSA21 database <http://chr21.molgen.mpg.de/hsa21>\[[@B4]\], a resource of RNA in situ hybridizations in postnatal mouse brain sections, in order to provide independent supporting evidence of brain expression of these 79 genes as shown for example for *BACH1*(basic leucine zipper transcription factor 1) and *TTC3*(tetratricopeptide repeat domain 3) (Figure [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}).

![**Brain-related dosage effects**. A) Venn diagram showing the overlap of the 324 significant genes with 623 genes identified by independent mouse studies related to brain phenotypes; B) RNA in situ hybridisations of *BACH1*in postnatal mouse embryonic brain slices. C) In situ hybridisation of *TTC3*in the same tissue. Images kindly provided by the HSA21 consortium (\[[@B4]\]; <http://chr21.molgen.mpg.de/hsa21>). D) Hierarchical clustering of 79 genes related to non-DS general brain disorders with the DS gene expression data sets. Clustering was performed with the J-Express 2009 software using Pearson correlation as similarity measure and complete linkage as update rule.](1471-2164-12-229-3){#F3}

Additionally, we investigated the expression patterns of the 79 genes across the DS microarray experiments used for this meta-analysis and could identify brain-related signatures, for example, a clear up-regulation in brain tissues for the cluster containing *C14orf147, IVSNS1ABP, B2M, TPJ1, SPARC, CTGF, COL4A1*and *FSTL1*(Figure [3D](#F3){ref-type="fig"}).

Novel Dosage Effects
--------------------

To identify DS-relevant \"novel\" dosage effects we excluded from the 324 genes *(i)*HSA21 genes, *(ii)*genes that interacted with HSA21 genes, as well as *(iii)*genes that were associated with DS in the literature (Table [4](#T4){ref-type="table"}). Remaining candidates (N = 62) comprised BDNF-related genes (*SST*), MAPK-pathway genes (*KRAS*, *IGF1R*, *GNG11*and *RAP1A*), genes related with leukemia (*SFRP1*) and Rho-Proteins (*DHCR7*and *RAB21*). *SST*was found as co-expressed in previous studies with *TAC1*\[[@B44]\] which is also significant in our meta-analysis and both showed a strong correlation across DS studies (Figure [4A](#F4){ref-type="fig"}).

###### 

Novel DS dosage effects

  ---------------------------------------------------------------------------------------------------
  Ensembl           HUGO       Score   Entropy   Chromo-some   Start\      End\        Band     CNV
                                                               position    position             
  ----------------- ---------- ------- --------- ------------- ----------- ----------- -------- -----
  ENSG00000133110   POSTN      8.301   2.437     chr13         38136722    38172981    q13.3    YES

  ENSG00000135919   SERPINE2   5.904   3.048     chr2          224839765   224904036   q36.1    

  ENSG00000172893   DHCR7      5.883   3.441     chr11         71145457    71159477    q13.4    

  ENSG00000135744   AGT        5.467   2.799     chr1          230838269   230850043   q42.2    

  ENSG00000159176   CSRP1      5.424   3.136     chr1          201452658   201478584   q32.1    

  ENSG00000178695   KCTD12     5.344   2.373     chr13         77454312    77460540    q22.3    

  ENSG00000183087   GAS6       5.129   2.904     chr13         114523524   114567046   q34      

  ENSG00000164106   SCRG1      5.127   2.728     chr4          174309300   174320617   q34.1    

  ENSG00000166923   GREM1      5.073   1.486     chr15         33010175    33026870    q13.3    YES

  ENSG00000163754   GYG1       4.933   3.129     chr3          148709128   148745419   q24      

  ENSG00000155380   SLC16A1    4.878   2.927     chr1          113454469   113499635   p13.2    YES

  ENSG00000166033   HTRA1      4.811   3.101     chr10         124221041   124274424   q26.13   YES

  ENSG00000145632   PLK2       4.785   2.811     chr5          57749809    57756087    q11.2    

  ENSG00000115380   EFEMP1     4.726   2.257     chr2          56093102    56151274    p16.1    

  ENSG00000060237   WNK1       4.637   2.765     chr12         862089      1020618     p13.33   YES

  ENSG00000103888   KIAA1199   4.581   0.885     chr15         81071684    81244117    q25.1    

  ENSG00000113810   SMC4       4.462   3.372     chr3          160117062   160152750   q25.33   

  ENSG00000198356   ASNA1      4.431   3.067     chr19         12848306    12859137    p13.2    

  ENSG00000122952   ZWINT      4.415   3.266     chr10         58116989    58121036    q21.1    

  ENSG00000157005   SST        4.401   1.954     chr3          187386694   187388187   q27.3    

  ENSG00000117519   CNN3       4.384   3.253     chr1          95362507    95392834    p21.3    

  ENSG00000107104   KANK1      4.352   2.508     chr9          470291      746105      p24.3    YES

  ENSG00000151414   NEK7       4.329   1.848     chr1          198126121   198291550   q31.3    

  ENSG00000044574   HSPA5      4.261   3.449     chr9          127997132   128003609   q33.3    

  ENSG00000128590   DNAJB9     4.251   3.241     chr7          108210012   108215294   q31.1    

  ENSG00000127920   GNG11      4.226   2.747     chr7          93551011    93555831    q21.3    

  ENSG00000008083   JARID2     4.161   3.203     chr6          15246527    15522253    p22.3    

  ENSG00000119938   PPP1R3C    4.159   3.036     chr10         93388199    93392858    q23.32   

  ENSG00000049245   VAMP3      4.146   3.036     chr1          7831329     7841492     p36.23   

  ENSG00000120694   HSPH1      4.129   3.310     chr13         31710762    31736502    q12.3    

  ENSG00000168214   RBPJ       4.127   3.291     chr4          26321332    26436753    p15.2    

  ENSG00000162909   CAPN2      4.111   3.020     chr1          223889347   223963720   q41      YES

  ENSG00000166147   FBN1       4.106   2.070     chr15         48700505    48937918    q21.1    YES

  ENSG00000100941   PNN        4.081   3.380     chr14         39644425    39652422    q21.1    

  ENSG00000132640   BTBD3      4.074   3.478     chr20         11871371    11907257    p12.2    YES

  ENSG00000128708   HAT1       4.064   3.158     chr2          172778958   172848599   q31.1    YES

  ENSG00000176105   YES1       4.047   2.855     chr18         721588      812327      p11.32   

  ENSG00000152377   SPOCK1     4.025   3.083     chr5          136310987   136835037   q31.2    

  ENSG00000136026   CKAP4      4.018   2.754     chr12         106631659   106641908   q23.3    

  ENSG00000198121   LPAR1      3.979   2.858     chr9          113635543   113800738   q31.3    

  ENSG00000140443   IGF1R      3.951   3.376     chr15         99192200    99507759    q26.3    

  ENSG00000198730   CTR9       3.891   3.310     chr11         10772803    10801287    p15.3    

  ENSG00000162616   DNAJB4     3.869   3.035     chr1          78444859    78483648    p31.1    

  ENSG00000104332   SFRP1      3.825   2.587     chr8          41119483    41166992    p11.21   

  ENSG00000116473   RAP1A      3.824   2.769     chr1          112084840   112259313   p13.2    

  ENSG00000172500   FIBP       3.804   3.309     chr11         65651211    65656010    q13.1    YES

  ENSG00000133703   KRAS       3.801   3.338     chr12         25358182    25403854    p12.1    

  ENSG00000163032   VSNL1      3.798   3.099     chr2          17720393    17838285    p24.2    

  ENSG00000134684   YARS       3.765   3.431     chr1          33240840    33283754    p35.1    

  ENSG00000105854   PON2       3.764   2.862     chr7          95034179    95064510    q21.3    

  ENSG00000148943   LIN7C      3.763   3.033     chr11         27516124    27528303    p14.1    

  ENSG00000162734   PEA15      3.747   3.418     chr1          160175127   160185166   q23.2    

  ENSG00000103187   COTL1      3.731   3.304     chr16         84599200    84651683    q24.1    YES

  ENSG00000198648   STK39      3.722   3.439     chr2          168810530   169104651   q24.3    

  ENSG00000100577   GSTZ1      3.713   2.759     chr14         77787230    77797939    q24.3    

  ENSG00000080371   RAB21      3.707   3.312     chr12         72148658    72181150    q21.1    YES

  ENSG00000136108   CKAP2      3.688   2.960     chr13         53029495    53050485    q14.3    

  ENSG00000066583   ISOC1      3.686   2.655     chr5          128430442   128449721   q23.3    

  ENSG00000143420   ENSA       3.681   3.276     chr1          150573327   150602098   q21.3    

  ENSG00000114353   GNAI2      3.680   3.138     chr3          50263724    50296787    p21.31   YES

  ENSG00000140105   WARS       3.671   2.994     chr14         100800125   100842680   q32.2    

  ENSG00000018625   ATP1A2     3.670   2.733     chr1          160085549   160113381   q23.2    
  ---------------------------------------------------------------------------------------------------

![**Novel DS dosage effects visualised with the web browser**. A) *SST*and *TAC1*have been previously reported as acting in a complex. The deregulated profile of these genes correlates was shown here with the fold-change view of the web browser. B) *HSPA5*is a novel gene for DS implicated in neurodegeneration which is also a target of the *ATF6*TF whose target set was enriched with significant genes. The histogram displays the p-values for this gene in individual studies. C) *KANK1*, a gene previously related with paternally inherited cerebral palsy, shows a consistent trend of up-regulation in the considered studies as shown with the fold-change view of the web browser.](1471-2164-12-229-4){#F4}

Novel candidates are associated with neurodegenerative disorders including Alzheimer\'s disease (*VSNL1*), prion disease (*SCRG1, HSPH1, HSPA5*(Figure [4B](#F4){ref-type="fig"}) and *CTR9*) and age-related degeneration (*GAS6*and *GNG11*). Moreover, candidates could explain evident DS features (Additional file [1](#S1){ref-type="supplementary-material"}, Table S5): *(i)*genes related to neurogenesis and neurite outgrowth (*LPAR1*\[[@B45]\], *LIN7C*, *JARID2*, *GREM1, SERPINE2, IGFR1*and *SPOCK1*) that could be related with mental retardation or cognitive impairment, *(ii)*genes involved in synapsis (*AGT, KRAS, ATP1A2, GNAI2, SST*and *LIN7C*) *(iii)*cytoskeletal related proteins (*KANK1*\[[@B46]\]; Figure [4C](#F4){ref-type="fig"}), *CKAP2, CKAP4, HAT1, NEK7*and *VAMP3*), *(iv)*macular degeneration genes \[[@B47]\] or genes (*HTRA1*and *EFEMP1*) associated with age-related visual problems \[[@B48]\], *(v)*genes *(AGT, CNN3, FBN1, RBPJ, PON2, POSTN, RAP1A, WNK1*and *STK39*) that were related with cardiac impairments and could be candidates to explain this DS characteristic \[[@B49]\], and *(vi)*genes related with cancer (*BTBD3*\[[@B50]\], *DNAJB4*\[[@B51]\], *FIBP*\[[@B52]\] and *GSTZ1*\[[@B53]\]) \[[@B54]\].

These examples show that the meta-analysis approach identified multiple additional genes that might be involved in DS pathology. In order to enable the community to check any particular gene of interest for DS relevance in the studies under analysis, we have agglomerated all information of the meta-analysis into a WEB-interface <http://ds-geneminer.molgen.mpg.de/>. Examples of possible views and information are shown in Figure [4](#F4){ref-type="fig"}.

Discussion
==========

The statistical meta-analysis approach was described previously by Rasche et al. \[[@B26]\]. The score computed with meta-analysis correlates with entropy (Figure [1A](#F1){ref-type="fig"}) indicating the ability to identify general dosage effects across many experiments that might be of more phenotypic relevance than very specific ones. Additional file [4](#S4){ref-type="supplementary-material"}, Figures S3A and B provide an overview of the different sources of data, including two organisms (human and mouse), different tissues (brain, heart and others), different stages of development (adult, postnatal, embryonic) and different mouse models (Ts65DN, Ts1Cje, Tc1). It is *per se*interesting that, in spite of such heterogeneity, common dosage effects could be identified at all and it should be highlighted that whole-genome data was fairly robust across experiments. Additional file [4](#S4){ref-type="supplementary-material"}, Figure S3D shows the overall correlation of the quantitative values of PCR and microarray values averaged from all experiments with only few genes in the non-concordant sectors of the graph (red points).

The score used in this analysis allows detecting genes that could be either up- or down-regulated in different studies. An overview of the fold-changes for the genes across the different experiments is given in Additional file [1](#S1){ref-type="supplementary-material"}, Table S6. Because genes might change their expression level depending on the developmental state, tissue or because of other variables, we expected that this flexibility allows checking the hypothesis of random disturbances as well as the hypothesis of increased expression of HSA21 genes. We detected a clear enrichment of up-regulated genes on the q-terminal part of HSA21 (Figure [1D](#F1){ref-type="fig"} and Additional file [3](#S3){ref-type="supplementary-material"}, Figure S2). However, not a single region was identified but rather several smaller regions on HSA21 that agglomerate a large amount of significant dosage effects. This finding was also elaborated before (Korbel et al. \[[@B38]\] and Lyle R et al. \[[@B39]\]) using two independent data sets to characterize the molecular HSA21 regions in a set of DS-patients with partial duplications.

We studied 255 HSA21 genes matched with the probe sets from the microarrays. Of these only 77 showed consistent dosage effects (Figure [1](#F1){ref-type="fig"}). While 165 HSA21 genes had score values different from zero indicating response in some of the microarray studies, 90 HSA21 genes were not responsive at all and provide evidence for a strong mechanism of dosage compensation. On the other hand, these figures could also reflect the limitation of detecting reliable fold-changes of low magnitude with microarray technology. Furthermore, experiments covered only a limited amount of tissues so that it is likely that some genes were missed simply because they were not responsive in the tissues under analysis. However, having brain as the dominant whole-genome sample source this should ensure expression of most of the genes. Microarray data was focused on the Affymetrix platform in order to reduce variance arising from platform inconsistencies. We have also compared our results with additional studies including own previous research \[[@B9]\] and others \[[@B55]\] and found relevance of selected dosage effects with respect to other tissues as well (data not shown). Additional cross-validation was performed with an independent microarray data set \[[@B10]\]. These authors compared human lymphoblastoid cell lines derived from DS patients and normal controls with a custom-made HSA21 array. Yahya-Graison et al. \[[@B10]\] divided the expression ratios in four classes: class I and class II genes were significantly up-regulated, while class III and class IV genes were either compensated or showed variable response. Our meta-analysis revealed a high-degree of concordance taking into account that the cell model, platform and the methodology used were completely different. The meta-analysis scores were significantly higher for class I and II genes than for class III and IV genes (P-value \<0.01, Additional file [5](#S5){ref-type="supplementary-material"}, Figure S4). 25 out of 39 class I-II genes revealed a significant score in our meta-analysis (75%).

In this study we monitored molecular interactions of HSA21 genes that might function as drivers of dosage effects (Figure [2A](#F2){ref-type="fig"}). For example, *(i) TJP1*(Tight junction protein ZO-1) interacts with two HSA21 genes, *JAM2*and *CLDN8*, *(ii) FOS*(FBJ murine osteosarcoma viral oncogene homolog) interacts with HSA21 genes *ETS2*, *SUMO3*, *RUNX1*and indirectly with *ERG*, *(iii) RHOQ*(ras homolog gene family, member Q) interacts directly with *ITSN1*and *TIAM1*and indirectly with *SYNJ*, and *(iv) PIK3R1*interacts directly with *IFNAR1*and indirectly with *IFNAR2*. It should be emphasized that current information on molecular interactions is far from complete, thus we either might miss important interactions not yet detected and/or we might count false positive interactions due to the high error rates of current annotations of interactions.

Several of the DS genes (N = 79) extrapolated to more general neurological phenotypes (Figure [3A](#F3){ref-type="fig"}). The dendrogram (Figure [3D](#F3){ref-type="fig"}) shows further interesting profiles of these genes in the DS samples under analysis: *(i)*differential gene expression in the cerebellum region versus whole \"brain\" or cerebrum areas which has been reported in other studies (e.g. Moldrich et al. \[[@B56]\]), *(ii)*different patterns of gene expression associated to particular developmental stages (P0, P15 and P30); these changes were reported before by Dauphinot el al. \[[@B57]\], and *(iii)*differences in ES studies.

We further analyzed human and mouse studies separately and found 182 significant dosage effects using only human and 107 dosage effects using only mouse data. The Venn diagram in Additional file [4](#S4){ref-type="supplementary-material"}, Figure S3C clearly shows the benefit in detecting additional dosage effects when mixing the two species. Overlapping dosage effects were detected for 29 genes with both analyses (Additional file [1](#S1){ref-type="supplementary-material"}, Table S7). Results for the human and mouse specific analyses can be found in Additional file [1](#S1){ref-type="supplementary-material"}, Tables S8 and S9. It should be noted here that comparisons between human and mouse using microarrays are inherently difficult and have limitations since the probes for the orthologous mouse and human genes do not correspond well. Furthermore, gene expression variation is generally higher in human individuals compared to mouse inbred strains. Nonetheless, the 107 genes found in the analysis of mouse data (derived from the different mouse models for trisomy 21) represent a core set of genes responsive across different DS mouse models and, thus, could be highly relevant for DS pathogenesis.

In addition to genes commonly related to DS, we have identified novel genes that can be associated with DS phenotypes, in particular with neural development and neurodegeneration. To our best knowledge, this study is the first meta-analysis of genome-wide transcript levels along with other data domains in DS research. The agglomerated data can be accessed through the WEB server at <http://ds-geneminer.molgen.mpg.de> and the identified dosage effects are a resource for further functional testing and therapeutic development.

Conclusions
===========

We have identified a set of 324 genes with consistent dosage effects from 45 different experiments related to DS. Since the meta-analysis was enriched with brain experiments, we were able to detect a high fraction of genes related to neuro-development, synapsis and neuro-degeneration. Moreover, our results give more information about known and new pathways related to DS and also about 62 novel candidates. The results of the meta-analysis as well as the source data have been made accessible for the community through a WEB interface.

Material and methods
====================

Selection and integration of DS resources
-----------------------------------------

Data sets were selected from heterogeneous technical platforms, different model systems (human cell lines, human tissues, mouse models) and different developmental stages (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). For each gene and for each source we computed a numerical value that measures its dosage effect. Data categories were either qualitative or quantitative. Qualitative data incorporated a total of 30 published manuscripts including reviews and semi-quantitative studies as well as two SAGE studies \[[@B21],[@B58]\] and were summarised to one score point in order to avoid over-scoring. Here, a \"1\" referred to the case that the gene was found as DS relevant in one (or more) studies. Quantitative data from differential gene expression studies such as Affymetrix microarrays, RT-PCR, MALDI and other quantitatives techniques were evaluated in order to extract comparable information across the different studies. We considered Affymetrix studies that provided the raw data (CEL file level). Raw data were extracted from Gene Omnibus Expression (GEO, \[[@B59]\]), Array Express \[[@B60]\] or were retrieved from the author\'s web pages (in total 16 data sets including human tissues and four different mouse models (Ts65Dn, Ts1Cje, Tc1 and Ts + HSA21). Furthermore, we incorporated 18 RT-PCR and MALDI data sets for which the authors displayed the information for all genes under study (either significant or not).

Mapping of gene IDs
-------------------

A central pre-requisiste of any meta-analysis approach is the consolidation of the different ID types, for example coming from different organisms and from different versions of chips. We used the Ensembl database (version 56) as the backbone annotation for all studies. IDs were mapped to human Ensembl gene IDs. Mapping and merging of the information was done within R and the BioConductor package. In total, information on 19,388 ENSEMBL genes was mapped.

Mapping SAGE IDs
----------------

Differential expressed tags were extracted from additional files of the studies. Identifiers (based on sequences) were cross-tagged with the information displayed in the updating tables (SAGEmap_Hs and SAGEmap_Mn) from the SAGE site <ftp://ftp.ncbi.nlm.nih.gov/pub/sage/mappings>.

Transcriptome data pre-processing and normalization
---------------------------------------------------

We incorporated only case-control studies in the meta-analysis in order to derive expression fold-changes. Affymetrix gene chip annotations were adapted from the latest genome annotation (version 12). Affymetrix data were normalized with GC RMA. For transcriptome case-control studies three pieces of information were stored for each gene; *(i)*the fold-change (DS vs. controls), *(ii)*the standard error of the fold-change from the replicated experiments in that study and *(iii)*the expression p-value (presence-call) that indicates whether or not the gene is expressed in the target samples under study. For RT-PCR and MALDI experiments we computed the fold-change of the mean expression (DS vs. controls) as well as the reported standard error of the ratio. When mean and standard variation for each group (DS and controls) was provided we calculated the ratios as well as their associated standard errors.

Scoring DS dosage effects across studies
----------------------------------------

In order to score the different categories of information such as binary counts and quantitative gene expression values, we summarized the scores of the individual experiments for each category. For microarray studies, the score of the *i*-th gene in the *j*-th study, s~ij~, was computed as described in Rasche et al. \[[@B26]\]:

Here r~ij~is the fold-change, p~ij~is the average detection p-value and e~ij~is the standard error of the ratio derived from the experimental replicates of the study. Thus, the fold-change is weighted with its reproducibility across the experimental replicates and with the likelihood of the gene being expressed in the study\'s case or control samples.

For RT-PCR and MALDI studies we applied the following equation:

Here r~ij~is the fold-change and e~ij~is the standard error of the ratio.

The total score of the gene was computed as the sum across all individual study scores.

Sampling for significance
-------------------------

In order to assess the significance of the overall gene scores we generated random scores by re-sampling the scores 50,000 times with replacement within the same study. Using the random distribution as background we assigned as significant those genes that were above the 99.9 percentile of the background distribution.

Judging consistency of dosage effects
-------------------------------------

For each gene, entropy of the score distribution was computed in order to quantify the relevance of the gene across many experiments. Let s~ij~be the score of the ith gene in the jth study, then E~i~is a measure for the uniformity of the score distribution over the individual experiments:

High entropy is assigned to a gene if many experiments contribute to the overall score whereas low entropy is assigned if only a few experiments contribute to the overall score.

Enrichment analysis
-------------------

Gene Set Enrichment Analysis (GSEA, \[[@B41]\]) of the 324 genes was performed with respect to pre-defined human pathways agglomerated from 22 pathway resources from the ConsensusPathDB (\[[@B40]\], <http://cpdb.molgen.mpg.de>. Over-representation analysis of TF target sets was performed with Fisher\'s test based on annotation from TRANSFAC \[[@B42]\]. Motif enrichment analyses were performed using AMADEUS \[[@B43]\] with significant genes as target sets and all the genes considered in the meta-analysis as background set.

Selection of independent brain experiments
------------------------------------------

In order to proof general brain relevance of the 324 genes, we collected DS-independent gene expression studies to decipher brain features, performed with Affymetrix technology and, with experiments deposited in GEO or ArrayExpress (Additional file [1](#S1){ref-type="supplementary-material"}, Table S4). Mostly, these experiments were performed in mouse tissues. For each study we collected one or more resulting gene lists that were evaluated using Gene Set Enrichment Analysis (GSEA, \[[@B41]\]) against the complete list of 19,388 genes ranked by score.
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###### Additional file 1

**Supplementary tables**. Table S1. Data sources used for meta-analysis. Table S2. The 324 candidate genes detected in the meta-analysis study. Table S3. Transcription factors and associated GO terms. Table S4. Cross-validation studies. Table S5. Functional annotation of novel candidates. Table S6. Fold-changes and qualitative data. Table S7. Human and mouse data overlap. Table S8. DS genes derived from meta-analysis of human data. Table S9. DS genes derived from meta-analysis of mouse data.
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###### Additional file 2

**Figure S1**. Enrichment of GO categories for organ, tissue and cell development with respect to the significant HSA21 genes (red bars), the significant non-HSA21 genes (green bars) and the non-significant genes (blue bars).
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###### Additional file 3

**Figure S2**. Genomic location of DS dosage effects in A) human B) mouse. Significant genes are marked in red, non-significant genes in white.
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###### Additional file 4

**Figure S3**. A) Categorization of the 35 qualitative studies, B) Categorization of the 34 quantitative studies. C) Venn diagram of dosage effects detected with mouse and human data alone and with the combination of all data, D) correlation between average PCR and microarray values for the detected 324 dosage effects.
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###### Additional file 5

**Figure S4**. Cross-validation with DS dosage effects detected with an HSA21 microarray \[[@B54]\]. Box-plots of meta-analysis scores (Y-axis) for class I and II (dosage effects) and class III and IV (compensation and variable expression) genes as judged by the authors.
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